Anti-CD20 antibody therapy is used for both cancer and autoimmune disease but has been shown to be associated with PneumocystisPneumocysti
<p>Eight week old female NOD mice were treated with 50 µg anti-CD20 and 7 days later various B-cell ...
Monoclonal antibodies (mAb) directed against CD20, either unmodified or in radiolabeled forms, have ...
We investigated if a short-term B cell depletion during the pre-clinical phase of SLE in BXSB mice i...
Pneumocystis is an opportunistic fungal pathogen that presents as a pulmonary pneumonia. Originally ...
Objective: To explore the B-cell depleting capacity of a low-dose (20 µg) subcutaneous mouse anti-CD...
International audienceAlloimmunization against RBCs can cause life-threatening delayed hemolytic tra...
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to al...
International audienceThe view that B lymphocytes are pathogenic in diverse pathological settings is...
International audienceAnti-CD20 monoclonal antibodies (mAbs) represent an effective treatment for a ...
In order to investigate the cellular immunoresponses mediated by chimeric anti-CD20 monoclonal antib...
CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but not stem o...
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 an...
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 an...
<p>B cells and humoral immunity are critical components of an effective immune response. However, B ...
Despite the demonstrated clinical effi-cacy of CD20 monoclonal antibody (mAb) for lymphoma therapy, ...
<p>Eight week old female NOD mice were treated with 50 µg anti-CD20 and 7 days later various B-cell ...
Monoclonal antibodies (mAb) directed against CD20, either unmodified or in radiolabeled forms, have ...
We investigated if a short-term B cell depletion during the pre-clinical phase of SLE in BXSB mice i...
Pneumocystis is an opportunistic fungal pathogen that presents as a pulmonary pneumonia. Originally ...
Objective: To explore the B-cell depleting capacity of a low-dose (20 µg) subcutaneous mouse anti-CD...
International audienceAlloimmunization against RBCs can cause life-threatening delayed hemolytic tra...
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to al...
International audienceThe view that B lymphocytes are pathogenic in diverse pathological settings is...
International audienceAnti-CD20 monoclonal antibodies (mAbs) represent an effective treatment for a ...
In order to investigate the cellular immunoresponses mediated by chimeric anti-CD20 monoclonal antib...
CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but not stem o...
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 an...
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 an...
<p>B cells and humoral immunity are critical components of an effective immune response. However, B ...
Despite the demonstrated clinical effi-cacy of CD20 monoclonal antibody (mAb) for lymphoma therapy, ...
<p>Eight week old female NOD mice were treated with 50 µg anti-CD20 and 7 days later various B-cell ...
Monoclonal antibodies (mAb) directed against CD20, either unmodified or in radiolabeled forms, have ...
We investigated if a short-term B cell depletion during the pre-clinical phase of SLE in BXSB mice i...
DOI